Drug Trial Radar · NCT04194775
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
534
Actual
Start
Dec 13, 2019
Primary completion
Jun 18, 2025
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- CStone PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with lenvatinib and placebo in combination with lenvatinib in the treatment of subjects with no prior systemic treatment and with unresectable advanced hepatocellular carcinoma (HCC). Subjects cannot be eligible for locoregional therapy. In this study, Nofazinlimab (CS1003) (or placebo) and lenvatinib are both considered as the study treatment while Nofazinlimab (CS1003) (or placebo) is the investigational product and lenvatinib is selected as the basic treatment for HCC.
Conditions
- Hepatocellular Carcinoma
Interventions
Nofazinlimab (CS1003)+LenvatinibDrug
Nofazinlimab (CS1003), intravenous (i.v.) administration every 21 days; Lenvatinib oral administration, once daily
Nofazinlimab (CS1003) Placebo+LenvatinibDrug
Nofazinlimab (CS1003) Placebo, i.v. administration every 21 days ; Lenvatinib oral administration, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From enrollment to end of follow-up, a median of 42.5 months
Locations
74 sites in 6 countries. Site status is shown where the registry gives one.
Southern California Research Center
Coronado, California
Inland Empire Liver Foundation
Rialto, California
Mercy Medical Center
Baltimore, Maryland
UMass Memorial Medical Center
Worcester, Massachusetts
Stony Brook University Cancer Clinical Trials
Stony Brook, New York
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
The First Affiliated Hospital Of Anhui Medical University
Hefei, Anhui, China
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Beijing You'an Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
The 900th Hospital of Joint Logistic Support Force of PLA
Fuzhou, Fujian, China
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Foshan First People's Hospital
Foshan, Guangdong, China
Nanfang Hospital
Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Guangzhou, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, China
Hainan General Hospital - Hepatology
Haikou, Hainan, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Luoyang Central Hospital
Luoyang, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Zhengzhou University - First Affiliated Hospital
Zhengzhou, Henan, China
hubei Cancer Hospital
Wuhan, Hubei, China
Tongji Hospital - Medical Oncology
Wuhan, Hubei, China
Hunan Cancer Hospital - Radiology
Changsha, Hunan, China
Hunan Provincial People's Hospital
Changsha, Hunan, China
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
The First People's Hospital of Huai'an
Huai'an, Jiangsu, China
Nantong Tumor Hospital
Nantong, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Yanbian University Hospital
Yanbian, Jilin, China
Jinan Military Region General Hospital of the People's Liber
Jinan, Shandong, China
Shangdong Provicial Qianfoshan Hospital
Jinan, Shandong, China
Affiliated Hospital Of Jining Medical University
Jining, Shandong, China
Linyi Cancer Hospital
Linyi, Shandong, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Shanghai Cancer Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.